Clinical trials: Ticagrelor
Platelet Aggregation Inhibitors, Aspirin
GM03 - Platelet RNA Signatures of Aspirin
This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into…
- Conditions
- Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
- Trial name
- NCT05278637
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Duke University
Platelet Reactivity
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients.
- Trial name
- NCT03679091
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Myocardial Infarction, Acute Coronary Syndrome
Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome
Elderly patients undergoing percutaneous coronary intervention (PCI) face a high risk of both ischemic and hemorrhagic complications necessitating antiplatelet therapy.
- Trial name
- LowASA-PCI (NCT06254391)
- Testing
- Low-dose aspirin
- Where
- Poland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Healthy
Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling
Ticagrelor is a new generation antiplatelet agent with higher efficacy as compared to clopidogrel and prasugrel in treatment of patients with moderate and high ischemic risks.
- Trial name
- NCT02435563
- Testing
- ticagrelor 180 mg administrated alone, Ticagrelor adjusted dose + ritonavir 100mg
- Where
- Switzerland
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Thrombosis
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender.
- Trial name
- NCT04945616
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
This is an open label study to assess the improvement in the Disease Activity Score for 28-joint counts (DAS28) with ticagrelor given at 90 mg twice daily in patients with RA who have active disease despite MTX therapy (as…
- Trial name
- TIMERA (NCT02874092)
- Testing
- Ticagrelor, MTX therapy
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Healthy
Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
This phase 2B study is a multi-center, randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy of bentracimab (PB2452) in reversing the anti-platelet effects of ticagrelor as part of a…
- Trial name
- NCT04122170
- Testing
- Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion
- Where
- 15 sites in United States, Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Healthy
PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males
This study is to characterize the pharmacokinetic and pharmacodynamics of ticagrelor and prasugrel in healthy Korean male subjects. The study is open label, one sequence, crossover design.
- Trial name
- NCT01876797
- Testing
- ticagrelor/prasugrel
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Pharmacodynamics
Clopidogrel And Ticagrelor in Healthy Subjects
To evaluate the pharmacodynamics of a lower Ticagrelor dose in healthy Korean volunteers compared with standard Clopidogrel agent.
- Trial name
- NCT02086903
- Testing
- Ticagrelor 90 mg, Clopidogrel 600 mg
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Acute Coronary Syndrome, Ischemic Stroke
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.
- Trial name
- NCT06584812
- Testing
- Tiprogrel, Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Atrial Fibrillation, Acute Coronary Syndrome
Triple vs. Dual Therapy
Background: The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality.
- Trial name
- NCT02080858
- Testing
- Ticagrelor + Apixaban + ASA, Ticagrelor + Apixaban
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Myocardial Infarction, Thrombosis
CES1 Crossover Trial of Clopidogrel and Ticagrelor
The purpose of this investigation is to evaluate when genetic variation in the carboxylesterase 1 (CES1) gene influences antiplatelet therapy response, as assessed by ex vivo platelet aggregometry, in healthy participants treated…
- Conditions
- Myocardial Infarction, Thrombosis, Platelet Dysfunction
- Trial name
- NCT03161678
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Healthy Subjects
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- TIC-025-23 (NCT06233266)
- Testing
- Ticagrelor-Test product, Ticagrelor-Reference product
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Coronary Artery Disease, Healthy Participants
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable…
- Trial name
- NCT05093790
- Testing
- Ticagrelor, BMS-986141, Aspirin
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran
Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new pharmacodynamic methods
- Trial name
- NCT01595854
- Testing
- dabigatran etexilate, Ticagrelor
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
Reversal of the Anti-platelet Effects of Ticagrelor
The purpose of this study is to determine the proportion of untreated donor platelets required to fully reverse the platelet inhibitory effects of ticagrelor and aspirin in healthy persons and patients with coronary artery…
- Trial name
- REVERSAL (NCT02383771)
- Testing
- Ticagrelor, Aspirin + Ticagrelor, Control
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Coronary Syndromes, Ticagrelor
Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea
This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital.
- Conditions
- Acute Coronary Syndromes, Ticagrelor, Dyspnea
- Trial name
- ACS (NCT07268859)
- Testing
- STANDART CARE, STANDART CARE & FAN THERAPY
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Acibadem University
Healthy
Ticagrelor and Adenosine
Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular uptake of adenosine via the equilibrative…
- Trial name
- NCT01996735
- Testing
- Ticagrelor 180 mg single dose
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center